The following activities will be carried out: survey of existing, ongoing, and planned risk assessment experimentations and evaluation of their impact on benefits; review of guidelines and identification of research gaps and implementation, and prioritised clinical questions for guideline updates; systematic review and multidisciplinary
analysis (consensus method) of cost-effectiveness models and socio-psychological impact, and Patient Reported Outcomes (PROMS); collection and analysis of data on feasibility, transferability, and challenges in different screening approaches; and development of a toolbox for critical analysis of screening strategies to support decision makers at national/local level (expected benefits, costs, cost-effectiveness).
This task will be led by Unicancer, France, co-led by CPO, Italy.